[018]Worth a lookBrazil · LatAm · Taiwan · KoreaHealth subscriptionData as of 2026-11-02
A local companion app for people paying out of pocket for weight-loss shots, subscription, only in countries that don't have a local version yet
B
Wait and watch: don't chase Brazil, LatAm, Taiwan or Korea, someone already holds each of theseThe valuable part is the approach: for people paying out of pocket and using the drug in a gray zone, work out "how many doses, where to buy, is it worth the money." Only enter a country that has just had a price drop and has no local app yet, and only if you already have a channel into local users of the drugMaybe · grade and headline derived from the full article · next review 12-01
| Background | Brazil's semaglutide patent expires in 3-20, and domestic versions are half price. Tirzepatide is smuggled in from Paraguay. About 6M people use it |
|---|---|
| Upside | Local drug names, small-vial conversions, format changes, hospital drug prices: local features US apps don't offer. Monju made it into Brazil's overall Top Grossing top 200. |
| Demand | Needs a human touch: community, real-person WhatsApp support. Hard paywalls, monthly prices shown for annual plans, 7-day refunds refused, data lost. |
| Competition | Spanish-speaking Latin America is already Monju; Taiwan has Molife and mojo from indie devs; Korea's 삐약 is free and has funding; Brazil's later entrants rank #59–133 |
| Revenue | The top two never published credible revenue. Rankings suggest tens of thousands per month. A comparable English product, TrustMRR, verifies $264–1,418/month, and six are listed for sale. |
| Growth | Getting traction through content: anonymous TikTok accounts, Instagram before-and-after posts, communities, Threads and LINE groups. Google ads have run 0 in the last 7 days. |
| Window | By drug price: generic prices in Mexico, Colombia, and Chile are 2026 to 2027; the only truly empty markets are Japan and mainland Europe, and demand there is unproven |
| Who it's for | Small teams that already have local health / weight-loss user channels and know the local language and medication habits. Solo developers who want to translate and port should stay away |
Latest
- 11-08Turkish app factory Codeway is testing this area with GLP-1 tracker Dosely. Its ad creatives went from 120 to 93 in a week. It has 78 App Store ratings and ranks #131 on Brazil's Top Free chart, but it hasn't scaled yet. The local-language gaps in Taiwan, Korea, and Latin America haven't been taken yet.
- 11-07Turkish app factory Codeway tested the Brazilian market with GLP-1 Tracker: Dosely. Within a week of running ads it went from 120 to 93 ads; the App Store shows only 78 ratings and it ranks #131 in Top Free, so it hasn't taken off. It's running English and multi-language versions, and the local-language gaps in Taiwan, Korea and LatAm haven't been taken yet.
- 11-06Turkish app factory Codeway launched GLP-1 Tracker "Dosely", running 120 ads, but the App Store shows only 78 ratings and it ranks #131 in Brazil's Top Free, so it hasn't taken off yet. It's going with English plus multiple languages; watch whether it adds local-language versions for Taiwan, Korea and LatAm.
- 11-05Turkish app factory Codeway has entered: GLP-1 Tracker "Dosely" is already running 120 ads, but the App Store shows only 78 ratings and it ranks #131 in Brazil's Top Free, so it hasn't taken off. It's running English and multi-language ads together. The open spots for local-language versions in Taiwan, Korea and LatAm depend on whether it localizes.
- 11-04Turkish app factory Codeway launched GLP-1 Tracker: Dosely, already running 120 ads, but the App Store shows only 78 ratings and it ranks #131 in Brazil's Top Free, so it hasn't taken off. It's running English and multi-language ads together. The open spots for local-language versions in Taiwan, Korea and LatAm depend on whether it localizes.